Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G Talon Capital Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A BridgeBio Oncology Thera Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Galata Acquisition Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A ZEVRA THERAPEUTICS, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G NORTHPOINTE BANCSHARES Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Highview Merger Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G MONRO, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G BRIGHT MINDS BIOSCIENCES Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: Adage Capital Management, L.P.
-
Cybin completes $175 million stock offering
-
Cybin Announces Closing of $175 Million Registered Direct Offering
-
Form SCHEDULE 13D/A 89bio, Inc. Filed by: Adage Capital Management, L.P.
-
Cybin raises $175 million in registered direct offering
-
Cybin Announces $175 Million Registered Direct Offering
-
Tango Therapeutics raises $225 million in stock offering
-
Tango Therapeutics Announces $225 Million Financing
-
Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity
-
Form SCHEDULE 13D 89bio, Inc. Filed by: Adage Capital Management, L.P.
-
Palisade Bio closes $138 million public offering to fund drug trial
-
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
-
UNCF Announces Dr. Shawn Thomas as Director of Investment Leadership Programs and Lead for Project ACCLAIM
-
CAMP4 raises up to $100 million for SYNGAP1 disorder treatment
-
CAMP4 raises up to $100 million for SYNGAP1 disorder treatment
-
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
-
PsiQuantum Raises $1 Billion to Build Million-Qubit Scale, Fault-Tolerant Quantum Computers
-
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: Adage Capital Management, L.P.
-
Form N-PX ADAGE CAPITAL PARTNERS For: Jun 30
-
Form N-PX Adage Capital Management For: Jun 30
-
iBio closes $50 million public offering led by Balyasny
-
iBio Announces Closing of $50 Million Public Offering
-
I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update
-
Form 13F-NT Adage Capital Management For: Jun 30
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Jun 30
-
Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Amylyx Pharmaceuticals, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G DBV Technologies S.A. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Adagio Medical Holdings, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Wave Life Sciences Ltd. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A ProQR Therapeutics N.V. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Seadrill Ltd Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Ensysce Biosciences, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Centessa Pharmaceuticals Filed by: Adage Capital Management, L.P.

